GB201517538D0 - Novel peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers - Google Patents

Novel peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers

Info

Publication number
GB201517538D0
GB201517538D0 GBGB1517538.3A GB201517538A GB201517538D0 GB 201517538 D0 GB201517538 D0 GB 201517538D0 GB 201517538 A GB201517538 A GB 201517538A GB 201517538 D0 GB201517538 D0 GB 201517538D0
Authority
GB
United Kingdom
Prior art keywords
peptides
cancers
combination
lung cancer
small cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1517538.3A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immatics Biotechnologies GmbH
Original Assignee
Immatics Biotechnologies GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immatics Biotechnologies GmbH filed Critical Immatics Biotechnologies GmbH
Priority to GBGB1517538.3A priority Critical patent/GB201517538D0/en
Publication of GB201517538D0 publication Critical patent/GB201517538D0/en
Priority to AU2016335177A priority patent/AU2016335177B2/en
Priority to PCT/EP2016/073416 priority patent/WO2017060169A1/en
Priority to PH1/2022/551111A priority patent/PH12022551111A1/en
Priority to CR20180191A priority patent/CR20180191A/es
Priority to KR1020187007972A priority patent/KR20180055826A/ko
Priority to EP16774689.0A priority patent/EP3359560A1/en
Priority to JP2018512283A priority patent/JP6868010B2/ja
Priority to US15/281,537 priority patent/US10253077B2/en
Priority to CR20200515A priority patent/CR20200515A/es
Priority to MA045424A priority patent/MA45424A/fr
Priority to CA3001074A priority patent/CA3001074A1/en
Priority to SG11201801344SA priority patent/SG11201801344SA/en
Priority to CR20200516A priority patent/CR20200516A/es
Priority to PE2018000322A priority patent/PE20181799A1/es
Priority to HK19100785.8A priority patent/HK1258386A1/zh
Priority to EA201890635A priority patent/EA201890635A1/ru
Priority to CN201680057635.2A priority patent/CN108699119A/zh
Priority to MA42021A priority patent/MA42021A1/fr
Priority to MYPI2018701254A priority patent/MY198087A/en
Priority to SG10202003124TA priority patent/SG10202003124TA/en
Priority to MX2018004140A priority patent/MX2018004140A/es
Priority to TW111129302A priority patent/TW202248208A/zh
Priority to TW105132155A priority patent/TWI755365B/zh
Priority to TW109133819A priority patent/TWI776245B/zh
Priority to ZA2018/01013A priority patent/ZA201801013B/en
Priority to IL257707A priority patent/IL257707A/en
Priority to CL2018000780A priority patent/CL2018000780A1/es
Priority to PH12018500665A priority patent/PH12018500665A1/en
Priority to CONC2018/0003659A priority patent/CO2018003659A2/es
Priority to US16/233,284 priority patent/US10377802B2/en
Priority to US16/237,279 priority patent/US10487126B2/en
Priority to US16/237,284 priority patent/US10597432B2/en
Priority to US16/504,126 priority patent/US10654903B2/en
Priority to US16/504,134 priority patent/US10597433B2/en
Priority to US16/591,323 priority patent/US10654904B2/en
Priority to US16/851,985 priority patent/US10899806B2/en
Priority to US16/851,976 priority patent/US11111280B2/en
Priority to AU2021201105A priority patent/AU2021201105B2/en
Priority to AU2021201104A priority patent/AU2021201104B2/en
Priority to AU2021201108A priority patent/AU2021201108A1/en
Priority to AU2021201107A priority patent/AU2021201107A1/en
Priority to AU2021201106A priority patent/AU2021201106B2/en
Priority to JP2021047883A priority patent/JP7344918B2/ja
Priority to JP2021047882A priority patent/JP7344917B2/ja
Priority to JP2021047884A priority patent/JP7344919B2/ja
Priority to CL2021001010A priority patent/CL2021001010A1/es
Priority to CL2021001012A priority patent/CL2021001012A1/es
Priority to CL2021001011A priority patent/CL2021001011A1/es
Priority to US17/333,579 priority patent/US11905319B2/en
Priority to US17/716,026 priority patent/US12173043B2/en
Priority to US18/947,499 priority patent/US20250074961A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/605—MHC molecules or ligands thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/55—Lung
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70539—MHC-molecules, e.g. HLA-molecules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7023—(Hyper)proliferation
    • G01N2800/7028—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
GBGB1517538.3A 2015-10-05 2015-10-05 Novel peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers Ceased GB201517538D0 (en)

Priority Applications (52)

Application Number Priority Date Filing Date Title
GBGB1517538.3A GB201517538D0 (en) 2015-10-05 2015-10-05 Novel peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
AU2016335177A AU2016335177B2 (en) 2015-10-05 2016-09-30 Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
PCT/EP2016/073416 WO2017060169A1 (en) 2015-10-05 2016-09-30 Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
PH1/2022/551111A PH12022551111A1 (en) 2015-10-05 2016-09-30 Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
CR20180191A CR20180191A (es) 2015-10-05 2016-09-30 Péptidos y combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer microcítico de pulmón y otros tipos de cáncer
KR1020187007972A KR20180055826A (ko) 2015-10-05 2016-09-30 소세포 폐암 및 기타 암에 대한 면역요법에서의 사용을 위한 펩티드 및 펩티드의 조합
EP16774689.0A EP3359560A1 (en) 2015-10-05 2016-09-30 Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
JP2018512283A JP6868010B2 (ja) 2015-10-05 2016-09-30 小細胞肺がんおよびその他のがんに対する免疫療法で使用するためのペプチドおよびペプチド組み合わせ
US15/281,537 US10253077B2 (en) 2015-10-05 2016-09-30 Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
CR20200515A CR20200515A (es) 2015-10-05 2016-09-30 Péptidos y combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer microcítico de pulmón y otros tipos de cáncer
MA045424A MA45424A (fr) 2015-10-05 2016-09-30 Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer du poumon à petites cellules et d'autres cancers
CA3001074A CA3001074A1 (en) 2015-10-05 2016-09-30 Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
SG11201801344SA SG11201801344SA (en) 2015-10-05 2016-09-30 Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
CR20200516A CR20200516A (es) 2015-10-05 2016-09-30 Péptidos y combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer microcítico de pulmón y otros tipos de cáncer (divisional exp. 2018-0191)
PE2018000322A PE20181799A1 (es) 2015-10-05 2016-09-30 Peptidos y combinacion de peptidos para el uso en la inmunoterapia contra el cancer microcitico de pulmon y otros tipos de cancer
HK19100785.8A HK1258386A1 (zh) 2015-10-05 2016-09-30 用於小细胞肺癌和其他癌症免疫治疗的肽和肽组合物
EA201890635A EA201890635A1 (ru) 2015-10-05 2016-09-30 Пептиды и комбинации пептидов для применения в иммунотерапии мелкоклеточного рака легких и других видов рака
CN201680057635.2A CN108699119A (zh) 2015-10-05 2016-09-30 用于小细胞肺癌和其他癌症免疫治疗的肽和肽组合物
MA42021A MA42021A1 (fr) 2015-10-05 2016-09-30 Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer du poumon à petites cellules et d'autres cancers
MYPI2018701254A MY198087A (en) 2015-10-05 2016-09-30 Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
SG10202003124TA SG10202003124TA (en) 2015-10-05 2016-09-30 Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
MX2018004140A MX2018004140A (es) 2015-10-05 2016-09-30 Peptidos y combinacion de peptidos para usarse en la inmunoterapia contra el cancer pulmonar microcelular y otros tipos de cancer.
TW111129302A TW202248208A (zh) 2015-10-05 2016-10-05 用於小細胞肺癌和其他癌症免疫治療的新型肽和肽組合物
TW105132155A TWI755365B (zh) 2015-10-05 2016-10-05 用於小細胞肺癌和其他癌症免疫治療的新型肽和肽組合物
TW109133819A TWI776245B (zh) 2015-10-05 2016-10-05 用於小細胞肺癌和其他癌症免疫治療的新型肽和肽組合物
ZA2018/01013A ZA201801013B (en) 2015-10-05 2018-02-14 Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
IL257707A IL257707A (en) 2015-10-05 2018-02-25 Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
CL2018000780A CL2018000780A1 (es) 2015-10-05 2018-03-26 Péptidos y combinación de péptidos para el uso en la inmunoterapia contra el cáncer microcítico de pulmón y otros tipos de cáncer
PH12018500665A PH12018500665A1 (en) 2015-10-05 2018-03-26 Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
CONC2018/0003659A CO2018003659A2 (es) 2015-10-05 2018-04-05 Péptidos y combinación de péptidos para el uso en la inmunoterapia contra el cáncer microcítico de pulmón y otros tipos de cáncer
US16/233,284 US10377802B2 (en) 2015-10-05 2018-12-27 Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
US16/237,279 US10487126B2 (en) 2015-10-05 2018-12-31 Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
US16/237,284 US10597432B2 (en) 2015-10-05 2018-12-31 Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
US16/504,126 US10654903B2 (en) 2015-10-05 2019-07-05 Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
US16/504,134 US10597433B2 (en) 2015-10-05 2019-07-05 Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
US16/591,323 US10654904B2 (en) 2015-10-05 2019-10-02 Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
US16/851,985 US10899806B2 (en) 2015-10-05 2020-04-17 Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
US16/851,976 US11111280B2 (en) 2015-10-05 2020-04-17 Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
AU2021201105A AU2021201105B2 (en) 2015-10-05 2021-02-19 Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
AU2021201104A AU2021201104B2 (en) 2015-10-05 2021-02-19 Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
AU2021201108A AU2021201108A1 (en) 2015-10-05 2021-02-19 Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
AU2021201107A AU2021201107A1 (en) 2015-10-05 2021-02-19 Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
AU2021201106A AU2021201106B2 (en) 2015-10-05 2021-02-19 Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
JP2021047883A JP7344918B2 (ja) 2015-10-05 2021-03-22 小細胞肺がんおよびその他のがんに対する免疫療法で使用するためのペプチドおよびペプチド組み合わせ
JP2021047882A JP7344917B2 (ja) 2015-10-05 2021-03-22 小細胞肺がんおよびその他のがんに対する免疫療法で使用するためのペプチドおよびペプチド組み合わせ
JP2021047884A JP7344919B2 (ja) 2015-10-05 2021-03-22 小細胞肺がんおよびその他のがんに対する免疫療法で使用するためのペプチドおよびペプチド組み合わせ
CL2021001010A CL2021001010A1 (es) 2015-10-05 2021-04-21 Péptidos y combinación de péptidos para el uso en la inmunoterapia contra el cáncer microcítico de pulmón y otros tipos de cáncer (divisional de la solicitud no. 201800780)
CL2021001012A CL2021001012A1 (es) 2015-10-05 2021-04-21 Péptidos y combinación de péptidos para el uso en la inmunoterapia contra el cáncer microcítico de pulmón y otros tipos de cáncer (divisional de la solicitud no. 201800780)
CL2021001011A CL2021001011A1 (es) 2015-10-05 2021-04-21 Péptidos y combinación de péptidos para el uso en la inmunoterapia contra el cáncer microcítico de pulmón y otros tipos de cáncer (divisional de la solicitud no. 201800780)
US17/333,579 US11905319B2 (en) 2015-10-05 2021-05-28 Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
US17/716,026 US12173043B2 (en) 2015-10-05 2022-04-08 Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
US18/947,499 US20250074961A1 (en) 2015-10-05 2024-11-14 Novel peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1517538.3A GB201517538D0 (en) 2015-10-05 2015-10-05 Novel peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers

Publications (1)

Publication Number Publication Date
GB201517538D0 true GB201517538D0 (en) 2015-11-18

Family

ID=54606079

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1517538.3A Ceased GB201517538D0 (en) 2015-10-05 2015-10-05 Novel peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers

Country Status (18)

Country Link
US (5) US10253077B2 (enExample)
EP (1) EP3359560A1 (enExample)
JP (4) JP6868010B2 (enExample)
KR (1) KR20180055826A (enExample)
CN (1) CN108699119A (enExample)
AU (3) AU2016335177B2 (enExample)
CA (1) CA3001074A1 (enExample)
CL (1) CL2018000780A1 (enExample)
CO (1) CO2018003659A2 (enExample)
CR (3) CR20180191A (enExample)
EA (1) EA201890635A1 (enExample)
GB (1) GB201517538D0 (enExample)
MA (2) MA45424A (enExample)
MX (1) MX2018004140A (enExample)
PE (1) PE20181799A1 (enExample)
SG (2) SG11201801344SA (enExample)
TW (1) TWI776245B (enExample)
WO (1) WO2017060169A1 (enExample)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201517538D0 (en) * 2015-10-05 2015-11-18 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
PH12022551111A1 (en) * 2015-10-05 2023-08-23 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
JP7075125B2 (ja) 2016-05-25 2022-05-25 イマティクス バイオテクノロジーズ ゲーエムベーハー 標的としてのおよび胆嚢がんおよび胆管がんおよびその他のがんに対する免疫療法で使用するための新規ペプチド、ペプチド組み合わせ
GB201609193D0 (en) 2016-05-25 2016-07-06 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides as targets for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers
GB201612043D0 (en) * 2016-07-11 2016-08-24 Crescendo Biologics Ltd Composition for treatment of disorders
WO2018089688A1 (en) 2016-11-09 2018-05-17 Jinjun Shi Restoration of tumor suppression using mrna-based delivery system
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
EP4317432A3 (en) 2016-12-08 2024-04-17 Immatics Biotechnologies GmbH T cell receptors with improved pairing
WO2019007974A1 (en) 2017-07-07 2019-01-10 Immatics Biotechnologies Gmbh NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY OF LUNG CANCER, INCLUDING NSCLC, CPPC AND OTHER CANCERS
KR20200026898A (ko) 2017-07-07 2020-03-11 이매틱스 바이오테크놀로지스 게엠베하 Nsclc, sclc 등 폐암 및 기타 암에 대한 면역요법에서의 사용을 위한 신규 펩티드 및 펩티드의 조합
US20190016802A1 (en) 2017-07-14 2019-01-17 Immatics Biotechnologies Gmbh Dual specificity polypeptide molecule
KR20210029298A (ko) * 2017-08-16 2021-03-15 드래곤플라이 쎄라퓨틱스, 인크. Nkg2d, cd16, 및 egfr, ccr4 또는 pd-l1에 결합하는 단백질
DE102017127984B4 (de) 2017-11-27 2019-12-05 Immatics US, Inc. Verfahren für die Vermehrung und Aktivierung von γδ-T-Zellen
KR20200119840A (ko) 2018-02-09 2020-10-20 이매틱스 유에스 인코포레이티드 T 세포의 제조 방법
DE102018107224A1 (de) 2018-02-21 2019-08-22 Immatics Biotechnologies Gmbh Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
DE102018108612A1 (de) 2018-03-21 2019-09-26 Immatics US, Inc. Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen
US20210115519A1 (en) * 2018-04-19 2021-04-22 The University Of Chicago Methods and kits for diagnosis and triage of patients with colorectal liver metastases
US10925947B2 (en) * 2018-06-29 2021-02-23 Immatics Biotechnologies Gmbh A*03 restricted peptides for use in immunotherapy against cancers and related methods
CN109485721A (zh) * 2018-11-23 2019-03-19 杜学明 一种获得肿瘤特异性t细胞受体的方法
WO2020123661A1 (en) * 2018-12-11 2020-06-18 Farokhzad Omid C Methods for treating cancer
US20200297768A1 (en) 2019-03-19 2020-09-24 Immatics US, Inc. Cd28 t cell cultures, compositions, and methods of using thereof
EP3739588A1 (en) * 2019-05-13 2020-11-18 Koninklijke Philips N.V. Assessment of multiple signaling pathway activity score in airway epithelial cells to predict airway epithelial abnormality and airway cancer risk
CN110398584B (zh) * 2019-05-23 2023-01-24 广东药科大学 血清Slit2作为结直肠癌诊治和转移监测标志物的应用
KR20220029584A (ko) 2019-05-27 2022-03-08 이매틱스 유에스 인코포레이티드 바이러스 벡터 및 입양 세포 요법에서 그 사용
AU2020286756A1 (en) 2019-06-06 2022-01-27 Immatics Biotechnologies Gmbh Sorting with counter selection using sequence similar peptides
CN118666956A (zh) * 2019-06-25 2024-09-20 蒙特利尔大学 肿瘤抗原肽、肽组合、核酸、负载体、疫苗及其用途
US20210032370A1 (en) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Recruiting agent further binding an mhc molecule
JP2023515131A (ja) 2020-02-24 2023-04-12 イマティクス ユーエス，アイエヌシー． がんおよび関連する悪性腫瘍の治療のためにｔ細胞を増殖させる方法
DE102020111571A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
DE102020106710A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
WO2022040631A1 (en) 2020-08-21 2022-02-24 Immatics US, Inc. Methods for isolating cd8+ selected t cells
US20240002845A1 (en) 2020-10-08 2024-01-04 Albert-Ludwigs-Universitat Freiburg Casp8ap2 antagonists for use in the prevention or treatment of cancer
WO2022125511A1 (en) * 2020-12-07 2022-06-16 Iogenetics, Llc Administration of anti-tumor vaccines
CR20230295A (es) 2020-12-31 2023-07-27 Immatics Us Inc Polipéptidos cd8, composiciones y métodos de uso de estos
KR20240004937A (ko) 2021-05-05 2024-01-11 이매틱스 바이오테크놀로지스 게엠베하 Bma031 항원 결합 폴리펩타이드
EP4392441A1 (en) 2021-08-24 2024-07-03 Immatics US, Inc. Selection of immune cells using peptide mhc complexes generated by conditional ligand exchange
US20230089392A1 (en) 2021-09-20 2023-03-23 Immatics US, Inc. Monocyte depletion of t cells populations for t-cell therapy
CN118541392A (zh) 2021-09-28 2024-08-23 准星生物医药有限公司 多种形式的分子复合物
WO2023081925A1 (en) 2021-11-08 2023-05-11 Immatics Biotechnologies Gmbh Adoptive cell therapy combination treatment and compositions thereof
US20250235517A1 (en) * 2022-03-30 2025-07-24 Iogenetics, Llc Tumor-associated antigens in brain tumors
WO2023212655A1 (en) 2022-04-28 2023-11-02 Immatics US, Inc. Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof
US20230348561A1 (en) 2022-04-28 2023-11-02 Immatics US, Inc. Dominant negative tgfbeta receptor polypeptides, cd8 polypeptides, cells, compositions, and methods of using thereof
KR20250018168A (ko) 2022-04-28 2025-02-04 이매틱스 유에스 인코포레이티드 막-결합된 il-15, cd8 폴리펩티드, 세포, 조성물, 및 이의 사용 방법
EP4519418A1 (en) 2022-05-05 2025-03-12 Immatics US, Inc. Methods for improving t cell efficacy
CN116189880A (zh) * 2023-01-21 2023-05-30 中国医学科学院北京协和医院 一种肺腺癌脑转移的预测指标及预测方法和应用
US20250134931A1 (en) 2023-11-01 2025-05-01 Immatics US, Inc. Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof
CN117384859B (zh) * 2023-12-13 2024-03-22 北京翊博生物集团有限公司 一种树突状细胞来源的外泌体的制备方法及应用
WO2026096743A1 (en) 2024-10-30 2026-05-07 Immatics US, Inc. Methods for gamma delta t cells manufacturing

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040005561A1 (en) * 2000-03-01 2004-01-08 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
US7919467B2 (en) * 2000-12-04 2011-04-05 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
US20060045881A1 (en) * 2004-08-26 2006-03-02 Board Of Regents, The University Of Texas System Anti-cancer vaccines
SI1760089T1 (sl) 2005-09-05 2009-12-31 Immatics Biotechnologies Gmbh S tumorjem povezani peptidi, ki se veĹľejo na molekule humanega levkocitnega antigena (HLA) razreda I ali II in ustrezno cepivo proti raku
CA2655933C (en) * 2006-06-23 2014-09-09 Alethia Biotherapeutics Inc. Polynucleotides and polypeptide sequences involved in cancer
TWI538685B (zh) * 2010-04-02 2016-06-21 腫瘤療法 科學股份有限公司 Ｅｃｔ２胜肽及含此胜肽之疫苗
GB201006360D0 (en) * 2010-04-16 2010-06-02 Immatics Biotechnologies Gmbh Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
GB201009222D0 (en) 2010-06-02 2010-07-21 Immatics Biotechnologies Gmbh Improved cancer therapy based on tumour associated antigens derived from cyclin D1
SG191977A1 (en) * 2011-02-01 2013-08-30 Genmab As Human antibodies and antibody-drug conjugates against cd74
WO2012161951A1 (en) * 2011-05-23 2012-11-29 AML Therapeutics, LLC Peptides for preventing or treating a disease or disorder associated with cbp or p300 misregulation, and methods for use and identification thereof
TWI714869B (zh) 2013-08-05 2021-01-01 德商伊瑪提克斯生物科技有限公司 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物
GB201517538D0 (en) 2015-10-05 2015-11-18 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers

Also Published As

Publication number Publication date
JP7344918B2 (ja) 2023-09-14
US10487126B2 (en) 2019-11-26
TW202124423A (zh) 2021-07-01
AU2021201107A1 (en) 2021-03-11
US20190119342A1 (en) 2019-04-25
CL2018000780A1 (es) 2018-06-01
JP7344917B2 (ja) 2023-09-14
CR20200515A (es) 2020-12-17
EA201890635A1 (ru) 2018-09-28
CN108699119A (zh) 2018-10-23
SG10202003124TA (en) 2020-05-28
US20190112347A1 (en) 2019-04-18
SG11201801344SA (en) 2018-04-27
MA45424A (fr) 2019-05-01
US20190161526A1 (en) 2019-05-30
JP6868010B2 (ja) 2021-05-12
US10597432B2 (en) 2020-03-24
MX2018004140A (es) 2018-06-06
AU2016335177A1 (en) 2018-04-12
EP3359560A1 (en) 2018-08-15
AU2016335177B2 (en) 2020-11-26
AU2021201108A1 (en) 2021-03-11
CO2018003659A2 (es) 2018-07-10
JP2018536383A (ja) 2018-12-13
PE20181799A1 (es) 2018-11-19
US20170096461A1 (en) 2017-04-06
WO2017060169A1 (en) 2017-04-13
CR20200516A (es) 2020-12-04
JP2021119772A (ja) 2021-08-19
TWI776245B (zh) 2022-09-01
MA42021A1 (fr) 2018-09-28
JP2021119773A (ja) 2021-08-19
JP2021126114A (ja) 2021-09-02
US10377802B2 (en) 2019-08-13
US20200048320A1 (en) 2020-02-13
JP7344919B2 (ja) 2023-09-14
CA3001074A1 (en) 2017-04-13
KR20180055826A (ko) 2018-05-25
US10253077B2 (en) 2019-04-09
US10654904B2 (en) 2020-05-19
CR20180191A (es) 2018-07-05

Similar Documents

Publication Publication Date Title
SG10202003124TA (en) Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
SG10202006119TA (en) Peptides and combination of peptides for use in immunotherapy against non-small cell lung cancer and other cancers
IL258599A (en) New peptides and a combination of peptides used in immunotherapy against breast cancer and other types of cancer
GB201511792D0 (en) Novel peptides and combination of peptides for use in immunotherapy against esopageal cancer and other cancers
ZA201800513B (en) Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
ZA201704939B (en) Novel peptides and combination of peptides for use in immunotherapy against lung cancer, including nsclc and other cancers
SG10202101368WA (en) Novel peptides and combination of peptides for use in immunotherapy against various cancers
ZA201707942B (en) Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
SG10202005950XA (en) Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
SG11201706155XA (en) Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
SG10202001665QA (en) Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
ZA201707810B (en) Novel peptides and combination of peptides for use in immunotherapy against esophageal cancer and other cancers
SG10202001485UA (en) Novel peptides and combination of peptides for use in immunotherapy against various tumors
IL254129A0 (en) New peptides and a combination of peptides for use in immunotherapy against various tumors
GB201604490D0 (en) Peptides combination of peptides for use in immunotherapy against cancers
IL254081B (en) New peptides and a combination of peptides for immunotherapeutic use against pancreatic cancer and other types of cancer
SG10202008013TA (en) Novel peptides and combination of peptides for use in immunotherapy against aml and other cancers
ZA201801013B (en) Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
EA202190896A3 (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии рака поджелудочной железы и других видов рака

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)